VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14

On October 31, 2019 VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, reported that it will host a conference call and live audio webcast on Thursday, November 14 at 8:30am Eastern Time to report third quarter and nine-months ended September 30, 2019 financial results and to provide a corporate update (Press release, VBL Therapeutics, OCT 31, 2019, View Source [SID1234550129]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thursday, November 14th @ 8:30am Eastern Time
From the US: 877-407-9208
International: 201-493-6784
Conference ID: 13696234
Webcast: View Source

The Mary Kay Foundation Awards $3.1 Million in Cancer Research and Domestic Violence Shelter Grants

On October 31, 2019 The Mary Kay FoundationSM reported that awarded over $3 million in cancer research and domestic violence shelter grants around the country (Press release, The Mary Kay Foundation, OCT 31, 2019, View Source [SID1234550145]). The Mary Kay Foundation was established in 1996 with the overarching purpose of eliminating cancers affecting women. In 2000, The Foundation expanded to include ending domestic violence as part of its mission.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

100 domestic violence shelters across the country, including Puerto Rico and the Virgin Islands, have been awarded $20,000 each, totaling $2 million. The Foundation is committed to funding the life-saving work of women’s shelters, and the annual shelter grant program has helped finance critical needs including emergency shelter, transitional housing, counseling and legal aid. All of these resources support women and children as they seek refuge and relief on their journey to an abuse-free life.

While a majority of domestic violence shelter grant recipients use the unrestricted funds for necessary operating expenses, others will complete repairs and facility renovations or add programs and resources based on the unique needs of their shelter and the clients they serve. Margie’s Haven House in Heber Springs, Arkansas, for example, plans to use their grant on a vehicle to help transport their clients to safety. In Decatur/Macon County, Illinois, and four surrounding counties, Dove, Inc. funds will be applied to the expense of increasing security to the entrance of their shelter. The exterior shelter door will be replaced with a fiberglass door, and an interior wall and an additional door will be added at the reception area.

Nearly 400,000 women and their families will receive domestic violence support services and free resources through the 100 agencies awarded.

After reviewing more than 70 applications, The Mary Kay Foundation Research Review Committee awarded $100,000 grants to 11 cancer research institutions across the country, totaling $1.1 million. This year’s grant recipients include the following leading research institutions:

Albert Einstein College of Medicine
Case Western Reserve University School of Medicine
Georgetown University
Michigan State University
University of California, San Francisco
University of Kansas Medical Center
University of Notre Dame
University of Utah
UT Southwestern Medical Center
Vanderbilt University Medical Center
Weill Cornell Medicine
"At The Mary Kay Foundation, we believe in helping women improve their circumstances and live their best lives," said Michael Lunceford, President of The Mary Kay Foundation Board of Directors. "Our Foundation seeks to do that in two critical ways: fund breakthrough research in our mission to eliminate cancers affecting women, and provide resources to domestic violence shelters across the country so they can aid survivors."

The Foundation’s 2019 cancer research grants will support many innovative studies. At Case Western Reserve University School of Medicine, Dr. Stefanie Avril is conducting groundbreaking research to harness the body’s immune system to eradicate breast cancer. At Georgetown University, Assistant Professor Dr. Cecil Han will utilize the grant to further her research on how changing metabolic pathways impacts the rapid growth and development of ovarian cancer cells in early stage. And at the University of Kansas Medical Center, Dr. Priyanka Sharma will use her 15 years of experience to research efforts on Triple Negative Breast Cancer, Novel Targeted Agents, Breast Cancer Genetics and Neoadjuvant Chemotherapy with the hopes of finding successful treatments for some of the most aggressive forms of breast cancer.

"We’ve seen previous grants lead to innovative breakthroughs in the study of breast, uterine, cervical and ovarian cancers, and are excited to see the research contributions of this year’s recipients," said Lunceford. "By continuing support for these scientists and institutions, we know we are continuing to better the lives of women everywhere."

Over the course of more than two decades, The Mary Kay FoundationSM has awarded more than $80 million to women’s shelters and domestic violence service providers, as well as cancer research programs and related causes throughout the United States.

AMP Workshop to Highlight Latest Clinical Research Data on Emerging Biomarkers in Cancer

On October 31, 2019 Thermo Fisher Scientific reported that it will host a series of customer presentations during its corporate workshops featuring the latest clinical research data on emerging biomarkers in cancer at the Association for Molecular Pathology (AMP) 2019 annual meeting on Nov. 6 (Press release, Thermo Fisher Scientific, OCT 31, 2019, View Source [SID1234550161]). The workshops will highlight details from studies in non-small cell lung cancer, immuno-oncology and hematology, and include the introduction of Thermo Fisher’s newest next generation sequencing (NGS) assay, Oncomine Comprehensive Assay Plus.*

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As the oncology biomarker landscape continues to evolve, greater clarity is needed to understand the prevalence and proper utilization of targeted and immuno-oncology biomarkers in tumor evaluation. Drs. Alain Mita, co-director of Experimental Therapeutics, and Eric Vail, director of Molecular Pathology at Cedars Sinai, will present data on RET fusions, the value of simultaneous assessment of comprehensive molecular results and the impact of faster turnaround times.

Ilaria Alborelli, Ph.D., scientist at the Institute of Pathology, University Hospital Basel, Switzerland, will deliver preliminary results from her assessment of Oncomine Comprehensive Assay Plus, a pan-cancer assay that covers more than 500 genes and enables simultaneous analysis of both DNA and RNA from just 10 ng in a single workflow. The new assay is designed to identify all classes of somatic variants, including SNVs, CNVs, fusions and splice variants, while also measuring tumor mutation burden (TMB) and microsatellite instability (MSI) – key biomarkers for emerging immunotherapies.

Dr. Yuri Fesko, medical director for oncology for Quest Diagnostics, will provide an overview of the limitations and best practices for TMB assessment results. The workshop will also feature comparison studies from Q2 Solutions which evaluated results from Oncomine TCR-Beta assays* with other on-market panels.

The rapid adoption of NGS to effectively assess driver mutations in hematology-oncology samples is providing many advantages and efficiencies over conventional molecular testing techniques. Speakers from the University of Nebraska Medical Center and Q2 Solutions will present their assessment of how to simplify analysis of myeloid and lymphoid samples using assays from Thermo Fisher’s portfolio of Oncomine panels, including Oncomine BCR IGH assays.*

For more information on the workshops taking place at the Baltimore Convention Center (9 a.m. E.T. Nov. 6, rooms 314-315) and other activities at AMP, please stop by Thermo Fisher’s booth (#2825), or visit the website.

* For Research use only. Not for use in diagnostic procedures

Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019

On October 31, 2019 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that it will report its third quarter 2019 financial results on Monday, November 4, 2019 (Press release, Iovance Biotherapeutics, OCT 31, 2019, View Source [SID1234550184]). Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 3482317. The live webcast can be accessed under "News & Events" in the Investors section of the Company’s website at www.iovance.com or at the link: View Source

OB-002 Significantly Reduces Bone Metastasis in a Murine Model of Breast Cancer

On October 31, 2019 Orion Biotechnology Canada, Ltd. reported that OB-002 was able to significantly reduce bone metastasis in a murine model of breast cancer (Press release, Orion Biotechnology, OCT 31, 2019, View Source [SID1234550114]). The study was conducted in collaboration with ProQinase (Heidelberg, Germany; View Source). Female BALB/c mice received orthotopic implantation of 4T1-M3_Luc cells into the mammary fat pad. The 4T1 breast cancer cells were transfected with firefly luciferase that allowed bioluminescent quantification of metastatic disease. Mice were randomized to receive placebo, OB-002, or a combination of OB-002 and an anti-PD-1. The OB-002 was administered via intraperitoneal (IP) injection daily (Monday through Friday) and the anti-PD-1 was administered IP every 3-4 days. The mice randomized to receive OB-002 at a dose of 20 mg/kg demonstrated a significant reduction in Day 20 primary tumor volume compared to placebo and the mice randomized to receive 80 mg/kg had a significant reduction in spinal bone metastasis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These data demonstrating that OB-002 can induce a significant reduction in both primary and metastatic breast cancer are very exciting and add to the growing body of data suggesting that OB-002 has the potential to play an important role in cancer therapy," said Dr. Ian McGowan, Chief Medical Officer for Orion Biotechnology. "Unfortunately, bone is the most common site of metastatic breast cancer (Ording AG et al., Clin Exp Metastasis 2017) and approximately 70% of women dying from breast cancer have bone metastases (Awolaran O et al., Breast 2016). Clearly, any product that has the potential to reduce breast cancer-associated bone metastasis would be a major advance in the field."

Mark Groper, President and CEO of Orion Biotechnology, added, "Breast cancer is the most common cancer in women worldwide and remains a challenging disease to manage. Bone metastasis is a frequent and debilitating complication of breast cancer and so these preliminary pre-clinical data are very encouraging."